logo
Popular back pain medication linked to brain health risks in some patients

Popular back pain medication linked to brain health risks in some patients

Fox News2 days ago
A painkiller used for lower back pain could be linked to a higher risk of dementia and mild cognitive impairment (MCI), according to new research.
The study, published online in the journal Regional Anesthesia & Pain Medicine, found that groups previously considered too young to develop the conditions faced more than twice the risk when taking gabapentin.
"Our findings indicate an association between gabapentin prescription and dementia or cognitive impairment within 10 years," the research team stated in a press release.
The drug has become increasingly popular for treating chronic pain, especially neuropathic (nerve) pain, the researchers noted in a press release.
Gabapentin — which is also used to control seizures, according to Cleveland Clinic — has relatively low addictive potential compared to traditional opioids.
Recent research has sparked new concerns over its side effects, including a possible association with neurodegeneration.
Previous findings could not confirm a specific link, especially regarding whether certain age groups are more vulnerable.
In the latest study, researchers collected data from TriNetX, a health research network containing electronic health records from 68 healthcare organizations across the U.S.
Examining anonymous records of adult patients, the team looked at groups who had been prescribed gabapentin for chronic lower back pain between 2004 and 2024 and compared them to people who hadn't received the drug. There were a total of 26,414 individuals in each group.
The researchers accounted for factors like demographics, co-existing conditions and the use of other pain-relieving drugs.
Patients who had received six or more gabapentin prescriptions were 29% more likely to be diagnosed with dementia and 85% more likely to be diagnosed with MCI within 10 years of their initial pain diagnosis, the study found.
Looking at specific age groups, people between 18 and 64 years old who received the drug were more than twice as likely to develop either condition than those who hadn't been prescribed gabapentin.
While there was no heightened risk among those aged 18 to 34 who were prescribed the drug, the risk of dementia more than doubled (and the risk of MCI more than tripled) among 35- to 49-year-olds.
Researchers observed a similar pattern among 50- to 64-year-olds.
Risks rose with prescription frequency: Patients with 12 or more prescriptions were 40% more likely to develop dementia and 65% more likely to develop MCI than those who were prescribed gabapentin between three and 11 times.
"Our findings indicate an association between gabapentin prescription and dementia or cognitive impairment within 10 years."
The study did have some limitations. As this was an observational study, no firm conclusions can be drawn about cause and effect, the researchers noted.
For more Health articles, visit www.foxnews.com/health
They also acknowledged that because the study was retrospective, they couldn't account for dose or length of gabapentin use.
The results "support the need for close monitoring of adult patients prescribed gabapentin to assess for potential cognitive decline," the researchers added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GSK seeks FDA nod for expanded use of RSV vaccine in adults
GSK seeks FDA nod for expanded use of RSV vaccine in adults

Yahoo

time16 minutes ago

  • Yahoo

GSK seeks FDA nod for expanded use of RSV vaccine in adults

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age of 50 at a higher risk of the disease. If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults. GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59. While it had a lead in approvals initially, it has since lagged behind rivals and sales have fallen sharply. The FDA is expected to make a decision on the expanded use of Arexvy in the first half of 2026, GSK said. European regulators are also expected to rule on a similar application by then. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report
DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report

Yahoo

time23 minutes ago

  • Yahoo

DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report

DaVita Inc. (NYSE:DVA) is one of the . On June 18, DaVita Inc. (NYSE:DVA) released its Community Care report, highlighting its long-standing commitment to corporate citizenship and development towards ESG goals for 2025. DaVita Inc. posted its major developments in 2024. In 2020, the company announced broadened ESG goals and has since reported progress against its five strategic focus areas, including Patient Care, Team Engagement, Environmental Stewardship, Healthy Communities, and Leading with Integrity and Accountability. The company's 100% global operations are on track to be matched by renewable energy purchases by 2025. Moreover, over 8,200 DaVita patients received a kidney transplant in 2024, the company's highest number of annual transplants to date. Chinnapong/ 'This year, we're reflecting on 25 years of patient care and progress made toward improving the health and vibrancy of the communities and people we serve. Looking ahead to the next 25 years, I'm excited about how we're positioned to build on these recent community health achievements to enhance the care experience for people around the world,' said Javier Rodriguez, chief executive officer for DaVita. DaVita Inc. (NYSE:DVA) is a healthcare provider focused on transforming care delivery to enhance the quality of life for patients worldwide. While we acknowledge the potential of DVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Can This Pacemaker Overcome Stubborn Hypertension?
Can This Pacemaker Overcome Stubborn Hypertension?

Medscape

time24 minutes ago

  • Medscape

Can This Pacemaker Overcome Stubborn Hypertension?

When medications for hypertension fail, or patients cannot adhere to the drugs, physicians may soon find themselves considering a new option for treating hypertension. Atrioventricular interval modulation (AVIM) therapy, a pacing algorithm incorporated into dual-chamber pacemakers, is being tested in patients with uncontrolled hypertension and a need for a pacemaker. Ongoing research could lead to a widened indication in patients who have uncontrolled blood pressure but do not need cardiac pacing, according to the developers of the technology. In April, the US FDA granted a Breakthrough Device Designation to Orchestra BioMed for its AVIM device, called BackBeat. According to the company, more than 7.7 million Americans meet the agency's criteria for this designation, having uncontrolled hypertension, preserved left ventricular systolic function, and a 10-year risk for atherosclerotic cardiovascular disease. David Hochman, the CEO of Orchestra BioMed, the company that created AVIM therapy, said a benefit of the technology is that it doesn't require patient adherence to medication. 'With hypertension, patients don't really necessarily feel symptoms, but they need to take medication to reduce the risk of high blood pressure, and they do feel side effects from the medicine.' Orchestra BioMed is collaborating with Medtronic on the BACKBEAT study, a randomized, double-blinded trial aiming to enroll approximately 500 patients. The MODERATO II study, on which the FDA designation was based, found patients who used the device experienced an 11.1 mm Hg ( P < .001) reduction in mean 24-hour ambulatory systolic blood pressure at 6 months, a 8.1 mm Hg greater than those managed only with antihypertensive medications. Older patients with isolated systolic hypertension are particularly challenging to manage. They 'are at higher risk of heart failure because of higher pulse pressure against a stiffer ventricle and stiffer blood vessels,' and they also are more challenging to treat,' Hochman said. 'It's a population with more unmet need and less dedicated research,' he added. Christopher DeSimone, MD, a cardiologist and electrophysiologist at Mayo Clinic in Rochester, Minnesota, said a nonpharmacologic option for uncontrolled hypertension is appealing because 'patients may have issues with compliance issues, polypharmacy and drug-drug interactions and face rising drug costs and fixed incomes.' However, he said he would like to see data showing this benefit is sustained in longer follow-up of 6-12 months. The 11 mg Hg reduction in systolic blood pressure seen in the MODERATO II trial is 'significant, and would play a big role for a lot of our patients.' A 2016 meta-analysis found every 10 mm Hg reduction in systolic blood pressure reduced the risk for major cardiovascular disease events by 20% and led to a 13% reduction in all-cause mortality. In those with pacemakers already, DeSimone said, 'the added risk of running the algorithm is essentially nothing. The patient would only stand to benefit and if not — the algorithm can be turned off.' But the implantation of a new pacing device for treating hypertension alone, he added, 'there are risks associated with the procedure, as well as infection risks given these reside in the bloodstream and can serve as a nidus for infection.' James Brian Byrd, MD, assistant professor at the University of Michigan, Ann Arbor, Michigan, and a cardiologist who researches and treats hypertension, said reducing blood pressure is 'really, really important from the perspective of public health and avoiding strokes and early deaths from heart attacks.' But he questioned whether the financial incentives of implanting a device could outweigh the incentives of adding on inexpensive medications. 'We have really well established and effective treatments that are inexpensive, that aren't used enough, and don't have champions necessarily for them,' Byrd said, referencing later-line hypertension therapies like spironolactone, amiloride, guanfacine, and eplerenone. Spironolactone, for example, is a generic drug that does not receive industry promotion, and while it can be effective in treating isolated systolic hypertension in particular, use of the m edication is associated with hyperkalemia. He worried that physicians could be financially incentivized to implant a device that does not require long-term follow-up 'as opposed to giving people medication where you have to check periodically to see whether their potassium is too high.' DeSimone agreed hypertension therapy falls short in many patients. 'It is quite difficult for the patient's family doctor to add on yet another therapy that takes time and resources to monitor in a situation that is already overwhelmed,' he said. As a result, the overwhelming majority of hypertension patients 'are not optimized, so they're not taking all of the therapies they could take or they've not been prescribed the right doses.' Hochman said that concerns that pacemakers would be overused for blood pressure are premature. Orchestra Med would need to 'produce very compelling data that satisfies regulators and ultimately satisfies the clinical community' before the pacemakers could be used to treat blood pressure alone, he explained. He added that pacemakers have become safer, with the advent of conduction system pacing. Pacemakers are also becoming easier to implant with the move toward leadless devices which are implanted fully in the heart and have a small footprint. DeSimone said the two other approved medical devices to treat blood pressure, baroreflex activation therapy and renal denervation, have had limited effectiveness and uptake. With AVIM technology 'by altering the physiology of the heart and the autonomic nervous system together, this device would fill a need that is currently lacking.' Hochman is the CEO of Orchestra BioMed, the company that created the AVIM pacemaker technology. Byrd has served on advisory boards for companies developing medications for hypertension. DeSimone reported having no relevant financial conflicts of interest.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store